Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.
The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A novel thymidine kinase mutation is described, along with a new phenotypic assay for characterizing acyclovir resistance in varicella zoster virus.
Hatchette
Todd
T
Department of Pathology, QEII Health Centre, Halifax, Nova Scotia, Canada.
Tipples
Graham A
GA
Peters
Geoff
G
Alsuwaidi
Ahmed
A
Zhou
Jianwei
J
Mailman
Timothy Lloyd
TL
D000212:Acyclovir / Q000494:pharmacology*; D002644:Chickenpox / Q000188:drug therapy* / Q000821:virology; D002648:Child; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use*; D014645:Herpesvirus 3, Human / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D009154:Mutation; D016879:Salvage Therapy / Q000379:methods*; D013937:Thymidine Kinase / Q000235:genetics*
D017245:Foscarnet; D013937:Thymidine Kinase; D000212:Acyclovir